GLPG3970
GLPG3970-CL-207
Phase 2 small_molecule terminated
Quick answer
GLPG3970 for Primary Sjögren Syndrome is a Phase 2 program (small_molecule) at Lakefront Biotherapeutics NV with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lakefront Biotherapeutics NV
- Indication
- Primary Sjögren Syndrome
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated